Fig. 2
From: Alemtuzumab for multiple sclerosis: the new concept of immunomodulation
On T and B cells expressing high concentrations of CD52, alemtuzumab (IgG1k) activates: 1) antibody-dependent cell-mediated (CD8 and NK) cytotoxicity (ADCC), 2) complement-dependent cytotoxicity (CDC), 3) caspase-dependent apoptosis